Skip to main content
    Q

    Quest Diagnostics Incorporated (DGX)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE

    $262.26
    +2.66 (+1.02%)

    Market Cap: $28.56B

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Quest Diagnostics Incorporated (DGX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Quest Diagnostics (DGX) to earn $11.32 per share in the fiscal year ending Dec 31, 2026, on revenue of $12.08B. Of 17 analysts, 9 rate the stock Buy or Strong Buy, 8 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 14 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 17 ratings average 2.35, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 53% of the ratings.

    RatingAnalystsShare
    Strong Buy211.8%
    Buy741.2%
    Hold847.1%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    17

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 5.8% and revenue estimates rise 4.5%.

    Fiscal year ending Dec 31, 2026
    $11.32
    EPS consensus, revenue $12.08B
    Fiscal year ending Dec 31, 2027
    $11.98
    EPS consensus, revenue $12.62B
    Next report
    Feb 8, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$11.32$11.25 to $11.4316$12.08B$12.06B to $12.10B15
    Dec 31, 2027$11.98$11.63 to $12.6716$12.62B$12.49B to $12.86B15

    Quarterly Estimates

    The EPS consensus falls from $2.71 for the quarter ending Dec 31, 2026 to $2.70 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$2.71$2.56 to $2.8817$3.07B$2.90B to $3.22B16
    Mar 31, 2027$2.70$2.59 to $2.8410$3.03B$3.00B to $3.08B7

    Estimate Revisions

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 2026141

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 1.2% from $11.19.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$11.32$11.32$11.20$11.19$11.19+1.1%
    Fiscal year ending Dec 31, 2027$11.98$11.98$12.03$12.06$12.06-0.6%
    Quarter ending Mar 31, 2027$2.70$2.76$2.77$2.77$2.76-2.4%

    Frequently Asked Questions About DGX

    What is the DGX stock forecast?

    Consensus analyst estimates put Quest Diagnostics's EPS at $11.32 for the fiscal year ending Dec 31, 2026, on revenue of $12.08B. The consensus rating from 17 analysts is Buy.

    How do analysts rate DGX stock?

    Of 17 analysts covering Quest Diagnostics, 2 rate it Strong Buy, 7 Buy, 8 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from DGX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $11.32, with estimates from $11.25 to $11.43 from 16 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $11.98, with estimates from $11.63 to $12.67 from 16 analysts.

    What revenue do analysts expect from Quest Diagnostics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $12.08B, with estimates from $12.06B to $12.10B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $12.62B, with estimates from $12.49B to $12.86B.

    How many analysts cover DGX?

    17 analysts rate Quest Diagnostics stock, and 16 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.